Doximity Inc - Class A risk profile
25 Normal where most of the sector sits
Measured 21 October 2026 from DOCS's filed statements. Recomputed nightly.
25 (Normal), driven by Market expectation at 76, over 6 weighted categories on the SOFTWARE profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 76 | Stretched | Volatile | One-year price volatility — 64.2% |
| Operating pressure | 59 | Elevated | Worsening | Costs outgrowing revenue — +13.3 percentage points |
| Cash conversion | 15 | Contained | Easing | Cash conversion — 1.67x |
| Leverage and coverage | 0 | Contained | Stable | Net debt to EBITDA — -0.91x |
| Competitive position | 21 | Normal | Stable | Revenue-growth gap against peers — +22.9 percentage points |
| Concentration | 14 | Contained | Stable | Customer concentration — 121 HHI |
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 33Johnson & Johnson 39Abbvie Inc 57Unitedhealth Group Inc 43Roche Holding AG 35Merck & Co Inc 35Novartis AG 29Novartis AG 31Astrazeneca plc 33Thermo Fisher Scientific Inc 44AMGEN Inc 47Gilead Sciences Inc 51
Financials, valuation and price history for Doximity Inc - Class A